Why bother to participate in clinical trials and observational studies? Because, without participation we will never have new treatments for Huntington's.
(pre-screening only) Enrolling date pending
Sponsor: Roche Pharmaceuticals
|This clinical trial will be testing the Ionis/Roche/Genetec antisense oligonucleotide (ASO) to study whether this drug will slow the progression of HD.
660 participants will be enrolled at 80-90 centers worldwide. Criteria include:
Study Description: Drug (and placebo) will be given into spinal fluid: All participants will have spinal fluid injections every 2 months with. 1/3 of participants to receive placebo, 1/3 to receive the drug every 2 months, 1/3 to receive drug every 4 months (at 2 months this group will receive placebo).
Sponsor: Vaccinex Inc
|This clinical trial is testing the safety of the VACCINEX developed Antibody (Pepinemab) in HD. Though not the primary goal, any changes in MRI scans and measures of disease progression will be assessed.
Though no longer enrolling, this trial is being conducted at:
|Enroll-HD study is a new international study that involves North America, Europe, South America and parts of Asia. Data from those of you who have already contributed to COHORT (with your permission) will added to Enroll-HD.
This study is an active collaboration of HD patients, individuals born at risk for HD (regardless of whether they have been tested genetically), and their families. It requires about a half day visit once a year. This study is vital to the more rapid development of treatments for HD therapeutics and completion of clinical trials. Visit EnrollHD.org for more information and updates.
Transportation reimbursement available.
|Muscle and Brain Biomarker Study
||The purpose of the study was to improve our ability to measure mitochondrial energy levels. No results officially reported. After limited study due to loss of funding this study was terminated.
|Predict-HD||To learn more about the progression of gene carriers from pre-symptomatic to diagnosis and progress of symptoms after diagnosis. This study was completed. Similar study is part of Enroll HD.
||This FDA approved drug showed benefit in treating HD chorea.
||This FDA approved drug showed benefit in treating HD chorea with fewer side effects reported for this drug than in the earlier tetrabenazine trial.
Though early trials looked promising this drug failed to show benefit.
PDE-10 Inhibitor drug. Terminated after adverse events reported.
||Phase 3 clinical trial testing creatine failed to show benefit.
||Though early trials looked promising this experimental drug failed in Phase 3 testing.
|COENZYME Q10||Phase 3 clinical trial that testing Coenzyme Q10 failed to show benefit.
||Phase 3 failed to show benefit.|